HOBOKEN, N.J., Aug. 2 /PRNewswire-AsiaNet/ — Approval Provides Seven Years of FDA Marketing Exclusivity Octapharma USA has received confirmation of orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for wilate(R) (von Willebrand Factor/Factor VIII Concentrate, Human), the replacement therapy developed specifically for von Willebrand Disease (VWD). The …
Read More »